College of Chemistry Advisory Board member, Andrew Ramelmeier, (Ph.D. '89, Chemical Engineering with Harvey Blanch) has just started a new position at Sangamo Therapeutics, a pioneer in gene based medicines, as SVP of operations after three years as the SVP of Technical Operations Biologics at Portola Pharmaceuticals. Dr. Ramelmeier recently spoke at the American Biomanufacturing Summit . In a taped interview, he offers very knowledgeable insight into the next five years in biomanufacturing and the growing need for talent.
Dr. Ramelmeier starts out by discussing that this is an exciting time to be in the biopharmaceutical industry. There is tremendous growth with new products and modalities coming online regularly. Talent will be a major issue over the next five years as the international need for new people will grow. "As I mentioned, sourcing and retaining talent will be a global issue," Dr. Ramelmeier states. "How do you manage that with multi-national companies and manufacturing in different locations?"
Find out more about the industry and its future by listening to the full interview here.
About Andrew Ramelmeier
Dr. Ramelmeier has over 20 years experience in the development and manufacturing of biopharmaceuticals, including monoclonal antibodies, vaccines, enzymes and other therapeutic proteins. He has been responsible for the licensure of several commercial products, process improvements to several more commercial products, and the design, construction and operation of 6 biologics production facilities, totaling over $400MM in investment. His technical expertise spans from cell culture and fermentation through purification, formulation and parenteral fill/finish. Dr. Ramelmeier received a B.S. in chemical engineering from Johns Hopkins University and his Ph.D. in chemical engineering from the University of California, Berkeley. He conducted post-doctoral work at the Institute for Enzyme Technology in Germany.